Announcements Trials
Browse Landscape

Phase

Phase 2 30Phase 1 13Phase NA 5Phase 1/2 4Phase 3 1Phase 2/3 1

Status

Completed 4Terminated 3Unknown 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 2Myelodysplastic Syndromes 1Lymphoma, T-Cell 1Lymphoma, B-Cell 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Hodgkin Disease 1Hematologic Neoplasms 1Graft vs Host Disease 1

Interventions

Cyclophosphamide 142Gemcitabine 129Paclitaxel 125Radiotherapy 119Cisplatin 111Carboplatin 111pembrolizumab 109Nivolumab 106Docetaxel 90Rituximab 86Lenalidomide 77Dexamethasone 76Cytarabine 69Bevacizumab 64Fluorouracil 63Etoposide 63Oxaliplatin 62Filgrastim 59Peripheral Blood Stem Cell Transplantation 58Everolimus 58Capecitabine 58fludarabine phosphate 57Doxorubicin 56Temozolomide 55Prednisone 54Irinotecan 53Cetuximab 50fludarabine 48Ipilimumab 48Erlotinib Hydrochloride 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × thymoglobulin × Clear all
NCT01701986 2025-02-28

Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Completed
64 enrolled 13 charts
Lymphoid

Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, T-Cell

NCT01664910 2024-07-23

CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

M.D. Anderson Cancer Center

Phase 1/2 Completed
27 enrolled 12 charts
Other hematologic neoplasm

Hematologic Neoplasms

NCT00822770 2020-10-14

Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin

M.D. Anderson Cancer Center

Phase 1/2 Completed
47 enrolled 8 charts
MyeloidOther hematologic neoplasm

Graft vs Host Disease, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

NCT00303667 2017-12-28

Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant

Masonic Cancer Center, University of Minnesota

Phase 1/2 Completed
50 enrolled 13 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡